14 February 2025
14 February 2025
These actions could postpone NIH-funded clinical trials and create cash flow issues for domestic biotech companies.
New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.
Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology arsenal.
The decision is supported by findings from the Phase III APPLY-PNH trial.
The company made an upfront payment and will provide success-based milestones and royalties in exchange for global rights.
The company signed the agreement with Karolinska Institutet's Department of Cell and Molecular Biology professor Johan Ericson.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
